Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and…
Vita Genomics
Last updated: 13.02.2014
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Company description
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Products and services
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
Interviews
Related
Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s…
Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their…
Louis Cheng – CEO, Leadgene Biomedical, Taiwan
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody…
Johnsee Lee – Chairman, Taiwan Bio Industry Organization; President &…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s…
First Impressions / Taiwanese Pharma
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that…
Report / New Taiwan Pharma Report November 2019 Out Now
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an…
APAC / Taiwanese Pharma Looking Locally for International Opportunities
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market,…
Talent / Multinationals' HR Strategies in Taiwan
All country managers of multinational pharma companies need to strike the balance between having a global outlook…
Stanley Huang – Founder & Managing Director, Nutrarex Biotech, Taiwan
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively…
APAC / Taiwan's New Southbound Policy: Enhancing Regional Ties
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland…
Company Profile / iXensor, Taiwan
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which…
Mark Yang – CEO, GaleMed, Taiwan
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned…
